Skip to content
Home/ Troubled Dream of Genetic Medicine: Ethnicity and Innovation in Tay-Sachs, Cystic Fibrosis, and Sick
Troubled Dream of Genetic Medicine: Ethnicity and Innovation in Tay-Sachs, Cystic Fibrosis, and Sick
Save Ask us

Troubled Dream of Genetic Medicine: Ethnicity and Innovation in Tay-Sachs, Cystic Fibrosis, and Sick

No customer reviews yet ISBN 9780801883255
Published
Mar 2006
Language
English
$79.25
In stock soon — order now to reserve your copy
This book can take longer to arrive. Shipping policy
Qty
Sign in to Add to Saved list
Free delivery over $35 · 15-day returns

Condition

Brand New

An unread, unused copy: no writing or highlighting, and no missing or damaged pages. Every book we sell is brand new, including our lowest-priced titles.

About this book

Winner of the History of Science category of the Professional and Scholarly Publishing Awards given by the Association of American Publishers

Why do racial and ethnic controversies become attached, as they often do, to discussions of modern genetics? How do theories about genetic difference become entangled with political debates about cultural and group differences in America? Such issues are a conspicuous part of the histories of three hereditary diseases: Tay-Sachs, commonly identified with Jewish Americans; cystic fibrosis, often labeled a "Caucasian" disease; and sickle cell disease, widely associated with African Americans.

In this captivating account, historians Keith Wailoo and Stephen Pemberton reveal how these diseases--fraught with ethnic and racial meanings for many Americans--became objects of biological fascination and crucibles of social debate. Peering behind the headlines of breakthrough treatments and coming cures, they tell a complex story: about different kinds of suffering and faith, about unequal access to the promises and perils of modern medicine, and about how Americans consume innovation and how they come to believe in, or resist, the notion of imminent medical breakthroughs.

With Tay-Sachs, cystic fibrosis, and sickle cell disease as a powerful backdrop, the authors provide a glimpse into a diverse America where racial ideologies, cultural politics, and conflicting beliefs about the power of genetics shape disparate health care expectations and experiences.

Specifications

PublishedMar 1, 2006
ISBN-100801883253
ISBN-139780801883255
LanguageEnglish

Buying from Saanjhi

  • Ships from the USA. Delivery to US addresses only.
  • Free delivery on orders over $35.
  • 15-day returns. Unless we send the wrong book or it arrives damaged, you pay return shipping and a 15% restocking fee.
  • Secure checkout. We never store card details.

Readers who bought this also bought

More from Genetics
See all
Polymers and Nanomaterials for Gene Therapy
<p><i>Polymers and Nanomaterials for Gene Therapy</i> provides the latest information on gene therapy, a topic that has attracted significant attention over the past two decades for the treatment of inherited and acquired genetic diseases. Major research efforts are currently focused on designing suitable carrier vectors that compact and protect oligonucleotides for gene therapy.</p> <p>The book explores the most recent developments in the field of polymer science and nanotechnology, and how these advancements have helped in the design of advanced materials. Non-viral vector systems, including cationic lipids, polymers, dendrimers, peptides and nanoparticles, are potential routes for compacting DNA for systemic delivery. However, unlike viral analogues that have no difficulty in overcoming cellular barriers and immune defense mechanisms, non-viral gene carriers consistently exhibit significant reduced transfection efficiency due to numerous extra- and intracellular obstacles. Therefore, biocompatibility and potential for large-scale production make these compounds increasingly attractive for gene therapy.</p> <p>This book contains chapters on the engineering of polymers and nanomaterials for gene therapy, and how they can form complexes with DNA and avoid both in vitro and in vivo barriers. Other chapters describe in vitro, ex vivo, in vivo gene therapy studies, and the current issues affecting non-viral gene therapy.</p>
$242.85